NCT03630991View on ClinicalTrials.gov

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

PHASE1RecruitingINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

October 11, 2018

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2027

Conditions
Acute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeBlast Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveChronic Myelogenous Leukemia, BCR-ABL1 PositiveHigh Risk Myelodysplastic SyndromeMyelodysplastic SyndromeMyelodysplastic/Myeloproliferative NeoplasmMyeloproliferative NeoplasmRecurrent Acute Myeloid LeukemiaRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRecurrent Myelodysplastic SyndromeRecurrent Myelodysplastic/Myeloproliferative NeoplasmRefractory Acute Myeloid LeukemiaRefractory Chronic Myelogenous Leukemia, BCR-ABL1 PositiveRefractory Myelodysplastic SyndromeSecondary Acute Myeloid LeukemiaSecondary Myelodysplastic SyndromeVery High Risk Myelodysplastic Syndrome
Interventions
DRUG

Edetate Calcium Disodium

Given IV

DIETARY_SUPPLEMENT

Multivitamin

Given PO

DRUG

Succimer

Given PO

Trial Locations (1)

77030

RECRUITING

M D Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER